SAGE - Sage TherapeuticsAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $83.45 | Open | $81.73 |
| Volume | 589.3K | Market Cap | 4.426B |
| Yield | Last Dividend |
| RBC Capital Stick to Their Hold Rating f... | 02/25/21 |
| RBC Capital Stick to Their Hold Rating for SAGE Therapeutics | |
| Sage Therapeutics Rises After Swing to P... | 02/24/21 |
| Sage Therapeutics traded higher after the biopharma posted a fourth-quarter profit, benefiting from its collaboration with Biogen. | |
| Sage Therapeutics Inc. (SAGE) Q4 2020 Ea... | 02/24/21 |
| Sage Therapeutics Inc. (NASDAQ: SAGE) Q4 2020 earnings call dated Feb. 24, 2021 Presentation: Operator Good morning. Welcome to Sage Therapeutics Four... | |
| Sage Therapeutics Announces Fourth Quart... | 02/24/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing ... | |
| Sage Therapeutics Will stock surge befor... | 02/23/21 |
| Sage Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| Sage Therapeutics (SAGE) Scheduled to Po... | 02/22/21 |
| Sage Therapeutics (NASDAQ:SAGE) will announce its earnings results before the market opens on Wednesday, February 24th. Analysts expect the company to... | |
| Sage Therapeutics to Present at Upcoming... | 02/11/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel t... | |
| The Daily Biotech Pulse: Bausch Health I... | 01/13/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) Abb... | |
| Canaccord Genuity Stick to Their Buy Rat... | 01/13/21 |
| Canaccord Genuity Stick to Their Buy Rating for SAGE Therapeutics | |
| Sage Therapeutics Provides 2021 Corporat... | 01/07/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel t... | |
| The Daily Biotech Pulse: FDA Nod For Amp... | 12/29/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Acl... | |
| Alnylam trailblazer Barry Greene makes t... | 12/16/20 |
| Sage Therapeutics will look to a new chief to lead the way during its comeback attempt. Former Alnylam president Barry Greene ??? a well known fixture... | |
| Sage Therapeutics Announces the Appointm... | 12/16/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapi... | |
| Mizuho Securities Stick to Their Buy Rat... | 12/13/20 |
| Mizuho Securities Stick to Their Buy Rating for SAGE Therapeutics | |
| Sage Therapeutics to Present at BMO 2020... | 12/03/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel th... | |
| Biogen, Sage Therapeutics Enter $1.5 Bil... | 11/27/20 |
| Biogen Inc will take a $650 million stake in Sage Therapeutics and pay $875 million in upfront payment as they jointly develop and sell treatments for... | |
| Biogen and Sage Therapeutics Announce Gl... | 11/27/20 |
| Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S. Biogen to receive exclusive license t... | |
| Sage Therapeutics (NASDAQ:SAGE) Price Ta... | 11/20/20 |
| Sage Therapeutics (NASDAQ:SAGE) had its price objective lifted by Oppenheimer from $65.00 to $94.00 in a report released on Thursday morning, The Fly ... | |
| Global Neuropsychiatric Drugs Market Ass... | 11/20/20 |
| InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on ???Global Neuropsychiatric Drugs Market Assessment ??? Revenue ... | |
| Morgan Stanley Lowers Sage Therapeutics ... | 11/20/20 |
| Morgan Stanley downgraded shares of Sage Therapeutics (NASDAQ:SAGE) from an overweight rating to an equal weight rating in a research report report pu... | |
| Sage Therapeutics Announces Third Quarte... | 11/05/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing ... | |
| Sage Therapeutics to Present at Upcoming... | 11/02/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel t... | |
| Royal Bank of Canada Boosts Sage Therape... | 10/23/20 |
| Sage Therapeutics (NASDAQ:SAGE) had its price target lifted by Royal Bank of Canada from $75.00 to $84.00 in a report released on Tuesday morning, The... | |
| SAGE Therapeutics (NASDAQ:SAGE) Stock Ra... | 10/23/20 |
| SAGE Therapeutics (NASDAQ:SAGE) was upgraded by stock analysts at BidaskClub from a ???buy??? rating to a ???strong-buy??? rating in a report released... | |
| Sage Therapeutics Announces Chief Execut... | 10/22/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing ... | |
| SAGE Therapeutics (NASDAQ:SAGE) Raised t... | 10/20/20 |
| SAGE Therapeutics (NASDAQ:SAGE) was upgraded by stock analysts at BidaskClub from a ???buy??? rating to a ???strong-buy??? rating in a research report... | |
| SAGE Therapeutics Inc (NASDAQ:SAGE) Rece... | 10/20/20 |
| Shares of SAGE Therapeutics Inc (NASDAQ:SAGE) have been assigned a consensus rating of ???Buy??? from the twenty-two analysts that are covering the fi... | |
| SAGE Therapeutics Inc (NASDAQ:SAGE) Shor... | 10/20/20 |
| SAGE Therapeutics Inc (NASDAQ:SAGE) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 6,21... | |
| SAGE Therapeutics (NASDAQ:SAGE) Price Ta... | 10/19/20 |
| SAGE Therapeutics (NASDAQ:SAGE) had its price objective lifted by BMO Capital Markets from $65.00 to $79.00 in a research report sent to investors on ... | |
| Sage Therapeutics to Report Third Quarte... | 10/19/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel t... | |
| Hold rating | 12:00 AM |
| Mizuho downgrades from Buy to Neutral rating and announces Price Target of $81.00 | |
| Strong Buy rating | 02/25/21 |
| Oppenheimer maintains Outperform rating and raises Price Target from $90.00 to $102.00 | |
| Buy rating | 01/22/21 |
| BMO Capital downgrades from Outperform to Market Perform rating and announces Price Target of $95.00 | |
| Hold rating | 01/04/21 |
| RBC Capital downgrades from Outperform to Sector Perform rating and raises Price Target from $83.00 to $86.00 | |
| Buy rating | 12/04/20 |
| Mizuho upgrades from Neutral to Buy rating and raises Price Target from $77.00 to $81.00 | |
| Hold rating | 12/01/20 |
| HC Wainwright & Co. maintains Neutral rating and lowers Price Target from $81.00 to $74.00 | |
| Hold rating | 12/01/20 |
| Morgan Stanley maintains Equal-Weight rating and lowers Price Target from $85.00 to $83.00 | |
| Date | 2021-02-24 (BMO) | Est. (EPS/Rev.) | ($0.35)/ 55.34M |
| Actual (EPS/Rev.) | $18.19/ $1.11 B | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| FEAT. ANDRE 3000 | JOHN KROLIKOWSKI JR | 92.00 % | Subscribe |
| WIDE AWAKE | JOHN KROLIKOWSKI JR | 82.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
